Literature DB >> 31375516

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia.

Christopher J Walker1, Jessica Kohlschmidt2,3, Ann-Kathrin Eisfeld2, Krzysztof Mrózek2, Sandya Liyanarachchi2, Chi Song4, Deedra Nicolet2,3, James S Blachly2, Marius Bill2, Dimitrios Papaioannou2, Christopher C Oakes2, Brian Giacopelli2, Luke K Genutis2, Sophia E Maharry2, Shelley Orwick2, Kellie J Archer2,4, Bayard L Powell5, Jonathan E Kolitz6, Geoffrey L Uy7, Eunice S Wang8, Andrew J Carroll9, Richard M Stone10, John C Byrd2, Albert de la Chapelle2, Clara D Bloomfield1.   

Abstract

PURPOSE: Uniparental disomy (UPD) is a way cancer cells duplicate a mutated gene, causing loss of heterozygosity (LOH). Patients with cytogenetically normal acute myeloid leukemia (CN-AML) do not have microscopically detectable chromosome abnormalities, but can harbor UPDs. We examined the prognostic significance of UPDs and frequency of LOH in patients with CN-AML.Experimental Design: We examined the frequency and prognostic significance of UPDs in a set of 425 adult patients with de novo CN-AML who were previously sequenced for 81 genes typically mutated in cancer. Associations of UPDs with outcome were analyzed in the 315 patients with CN-AML younger than 60 years.
RESULTS: We detected 127 UPDs in 109 patients. Most UPDs were large and typically encompassed all or most of the affected chromosome arm. The most common UPDs occurred on chromosome arms 13q (7.5% of patients), 6p (2.8%), and 11p (2.8%). Many UPDs significantly cooccurred with mutations in genes they encompassed, including 13q UPD with FLT3-internal tandem duplication (FLT3-ITD; P < 0.001), and 11p UPD with WT1 mutations (P = 0.02). Among patients younger than 60 years, UPD of 11p was associated with longer overall survival (OS) and 13q UPD with shorter disease-free survival (DFS) and OS. In multivariable models that accounted for known prognostic markers, including FLT3-ITD and WT1 mutations, UPD of 13q maintained association with shorter DFS, and UPD of 11p maintained association with longer OS.
CONCLUSIONS: LOH mediated by UPD is a recurrent feature of CN-AML. Detection of UPDs of 13q and 11p might be useful for genetic risk stratification of patients with CN-AML. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31375516      PMCID: PMC6825549          DOI: 10.1158/1078-0432.CCR-19-0725

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  56 in total

1.  A genome-wide association study yields five novel thyroid cancer risk loci.

Authors:  Julius Gudmundsson; Gudmar Thorleifsson; Jon K Sigurdsson; Lilja Stefansdottir; Jon G Jonasson; Sigurjon A Gudjonsson; Daniel F Gudbjartsson; Gisli Masson; Hrefna Johannsdottir; Gisli H Halldorsson; Simon N Stacey; Hannes Helgason; Patrick Sulem; Leigha Senter; Huiling He; Sandya Liyanarachchi; Matthew D Ringel; Esperanza Aguillo; Angeles Panadero; Enrique Prats; Almudena Garcia-Castaño; Ana De Juan; Fernando Rivera; Li Xu; Lambertus A Kiemeney; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Isleifur Olafsson; Hoskuldur Kristvinsson; Romana T Netea-Maier; Thorvaldur Jonsson; Jose I Mayordomo; Theo S Plantinga; Hannes Hjartarson; Jon Hrafnkelsson; Erich M Sturgis; Unnur Thorsteinsdottir; Thorunn Rafnar; Albert de la Chapelle; Kari Stefansson
Journal:  Nat Commun       Date:  2017-02-14       Impact factor: 14.919

2.  Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.

Authors:  A Stengel; W Kern; M Meggendorfer; N Nadarajah; K Perglerovà; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2017-07-28       Impact factor: 11.528

3.  RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.

Authors:  Susanne Schnittger; Frank Dicker; Wolfgang Kern; Nicole Wendland; Jana Sundermann; Tamara Alpermann; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

4.  New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.

Authors:  Ramon V Tiu; Lukasz P Gondek; Christine L O'Keefe; Jungwon Huh; Mikkael A Sekeres; Paul Elson; Michael A McDevitt; Xiao Fei Wang; Mark J Levis; Judith E Karp; Anjali S Advani; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

5.  Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia.

Authors:  Manu Gupta; Manoj Raghavan; Rosemary E Gale; Claude Chelala; Christopher Allen; Gael Molloy; Tracy Chaplin; David C Linch; Jean-Baptiste Cazier; Bryan D Young
Journal:  Genes Chromosomes Cancer       Date:  2008-09       Impact factor: 5.006

6.  Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Authors:  Eyal C Attar; Jeffrey L Johnson; Philip C Amrein; Gerard Lozanski; Martha Wadleigh; Daniel J DeAngelo; Jonathan E Kolitz; Bayard L Powell; Peter Voorhees; Eunice S Wang; William Blum; Richard M Stone; Guido Marcucci; Clara D Bloomfield; Barry Moser; Richard A Larson
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

7.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Authors:  Maria E Figueroa; Sanne Lugthart; Yushan Li; Claudia Erpelinck-Verschueren; Xutao Deng; Paul J Christos; Elizabeth Schifano; James Booth; Wim van Putten; Lucy Skrabanek; Fabien Campagne; Madhu Mazumdar; John M Greally; Peter J M Valk; Bob Löwenberg; Ruud Delwel; Ari Melnick
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

8.  The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.

Authors:  A-K Eisfeld; K Mrózek; J Kohlschmidt; D Nicolet; S Orwick; C J Walker; K W Kroll; J S Blachly; A J Carroll; J E Kolitz; B L Powell; E S Wang; R M Stone; A de la Chapelle; J C Byrd; C D Bloomfield
Journal:  Leukemia       Date:  2017-03-24       Impact factor: 11.528

9.  Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).

Authors:  W Blum; B L Sanford; R Klisovic; D J DeAngelo; G Uy; B L Powell; W Stock; M R Baer; J E Kolitz; E S Wang; E Hoke; K Mrózek; J Kohlschmidt; C D Bloomfield; S Geyer; G Marcucci; R M Stone; R A Larson
Journal:  Leukemia       Date:  2016-09-13       Impact factor: 11.528

10.  Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.

Authors:  Christopher J Walker; Christopher C Oakes; Luke K Genutis; Brian Giacopelli; Sandya Liyanarachchi; Deedra Nicolet; Ann-Kathrin Eisfeld; Markus Scholz; Pamela Brock; Jessica Kohlschmidt; Krzysztof Mrózek; Marius Bill; Andrew J Carroll; Jonathan E Kolitz; Bayard L Powell; Eunice S Wang; Dietger W Niederwieser; Richard M Stone; John C Byrd; Sebastian Schwind; Albert de la Chapelle; Clara D Bloomfield
Journal:  Leukemia       Date:  2018-10-05       Impact factor: 11.528

View more
  1 in total

Review 1.  Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.

Authors:  Aliaa Arina Rosli; Adam Azlan; Yaashini Rajasegaran; Yee Yik Mot; Olaf Heidenreich; Narazah Mohd Yusoff; Emmanuel Jairaj Moses
Journal:  Clin Exp Med       Date:  2022-10-13       Impact factor: 5.057

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.